angiotensin ii has been researched along with liraglutide in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 5 (62.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, F; Li, XW; McKallip, RJ; Pang, XF; Shah, AI; Wang, NP; Wang, X; Zhang, LH; Zhao, ZQ | 1 |
| Brdar, M; Dear, AE; Gaspari, T; Hu, Y; Lee, HW; Simpson, RW; Spizzo, I; Widdop, RE | 1 |
| Christiansen, JS; Dejgaard, A; Frøkiaer, J; Goetze, JP; Holst, JJ; Jonassen, T; Madsen, B; Pedersen, M; Rittig, S; Skov, J | 1 |
| Boogerd, CJ; de Boer, RA; Dokter, MM; Lam, CSP; Markousis-Mavrogenis, G; Meems, LMG; Schouten, EM; Silljé, HHW; Voors, AA; Westenbrink, BD; Withaar, C | 1 |
| Fan, S; Niu, Y; Qin, J; Shi, Y; Wang, J; Xiong, Q; Zhang, L; Zhang, X | 1 |
| Bai, F; Banks, TE; Rajapaksha, M; Wang, NP; Zhang, LH; Zhao, ZQ | 1 |
| Guo, R; Li, C; Ma, X; Wang, J; Wang, Y; Zhang, J; Zhang, Q; Zheng, N | 1 |
| Nguyen, J; Vandemark, C; Zhao, ZQ | 1 |
1 review(s) available for angiotensin ii and liraglutide
| Article | Year |
|---|---|
Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update.
Topics: Angiotensin II; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Heart Failure; Humans; Hypertension; Hypoglycemic Agents; Liraglutide | 2023 |
1 trial(s) available for angiotensin ii and liraglutide
| Article | Year |
|---|---|
Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
Topics: Adult; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Heart Rate; Humans; Kidney; Kidney Function Tests; Liraglutide; Male; Middle Aged; Placebos; Renal Circulation; Renin-Angiotensin System | 2016 |
6 other study(ies) available for angiotensin ii and liraglutide
| Article | Year |
|---|---|
Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT 2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Pressure; Collagen; Fibrosis; Gene Expression; Glucagon-Like Peptide 1; Linagliptin; Liraglutide; Male; Myocardium; Peptidyl-Dipeptidase A; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Smad Proteins; Transforming Growth Factor beta1 | 2015 |
Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.
Topics: Aging; Angiotensin II; Animals; Aorta; Blood Pressure; Body Weight; Chemokine CCL2; Diet, High-Fat; Disease Models, Animal; Endothelium, Vascular; Fibrosis; Glucagon-Like Peptide-1 Receptor; Heart; Heart Diseases; Hypertension; I-kappa B Proteins; Immunohistochemistry; Incretins; Inflammation; Interleukin-10; Liraglutide; Macrophages; Male; Mice; Mice, Inbred C57BL; Myocardium; NF-kappa B p50 Subunit; Obesity; Oxidative Stress; Real-Time Polymerase Chain Reaction; Vasoconstrictor Agents; Vimentin | 2016 |
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
Topics: Angiotensin II; Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Disease Models, Animal; Female; Fibrosis; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Glucosides; Heart Failure, Diastolic; Hypertrophy, Left Ventricular; Incretins; Liraglutide; Mice, Inbred C57BL; Myocardium; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways.
Topics: Adenylate Kinase; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cell Line; Disease Models, Animal; Glucagon-Like Peptide 1; Hypertension; Liraglutide; Male; Morpholines; Myocytes, Cardiac; Piperidines; Rats; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Triazines; Uracil | 2021 |
Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension.
Topics: Angiotensin II; Animals; Cardiomyopathies; Fibrosis; Glucagon-Like Peptide 1; Hypertension; Linagliptin; Liraglutide; Mitochondria; NADPH Oxidase 4; Rats; Rats, Sprague-Dawley | 2022 |
Liraglutide inhibits AngII-induced cardiac fibroblast proliferation and ECM deposition through regulating miR-21/PTEN/PI3K pathway.
Topics: Angiotensin II; Animals; Cell Movement; Cell Proliferation; Extracellular Matrix; Fibroblasts; Fibrosis; Liraglutide; Mice; Mice, Inbred C57BL; MicroRNAs; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2023 |